Small-Cap REIT ETF ...
Health Care: Drugs
Endocyte Inc. (ECYT: NASDAQ)
$14.38 0.12 | 0.84%
05/17/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 34.68M | 191.02K | 0.00 | 3.00M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 34.68M | 191.02K | 0.00 | 3.00M |
| Selling, General, and Administrative Expenses | 15.05M | 10.00M | 6.04M | 3.93M |
| Research & Development | 35.67M | 28.83M | 14.56M | 14.80M |
| Operating Income before D & A (EBITDA) | -16.04M | -38.64M | -20.60M | -15.74M |
| Depreciation & Amortization | 358.37K | 262.52K | 260.57K | 231.89K |
| Interest Income | 327.74K | 129.45K | 7.68K | 49.32K |
| Other Income - Net | -947.83K | -36.47K | 1.56M | 118.99K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -17.02M | -38.81M | -19.29M | -15.80M |
| Interest Expense | 628.99K | 1.99M | 1.06M | 1.44M |
| Pre-Tax Income | -17.65M | -40.79M | -20.35M | -17.24M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -17.29M | -40.53M | -20.09M | -17.01M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -17.29M | -40.53M | -20.09M | -17.01M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -17.29M | -40.53M | -20.09M | -17.01M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-17.29M | -40.53M | -20.09M | -17.01M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -17.29M | -40.53M | -20.09M | -17.01M |
| Basic EPS from Continuing Ops. | -0.48 | -1.40 | -21.77 | -1.34 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.48 | -1.40 | -21.77 | -1.34 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.48 | -1.40 | -21.77 | -1.34 |
| Basic Normalized Net Income/Share | -0.48 | -1.40 | -21.77 | -1.34 |
| EPS fr Continuing Ops. | -0.48 | -1.40 | -21.77 | -1.34 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.48 | -1.40 | -21.77 | -1.34 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.48 | -1.40 | -21.77 | -1.34 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.48 | -1.40 | -21.77 | -1.34 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ECYT
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- UserSmart Growth
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusal Vol...
- Contributor8 Health Care Stocks With R...
Latest ECYT Headlines from TheStreet
- Endocyte Announces First Quarter 2013 Earnings Conference Call 04.18.13 | 04:04 pm
- Endocyte Announces Presentations At AACR Annual Meeting 2013 04.03.13 | 04:04 pm
- Endocyte To Present At The Future Leaders In The Biotech Industry Conference 04.01.13 | 08:04 am
- Endocyte To Webcast Investor And Analyst Day In New York City 03.18.13 | 09:03 am
- Endocyte's Investigational Diagnostic Imaging Agent Etarfolatide Identifies Ovarian Cancer And Non-Small Cell Lung Cancer Patients Most Likely To Benefit From Folate Receptor-Targeted Treatment, New Analysis Shows 03.01.13 | 03:03 pm
- Endocyte To Present At Upcoming Conferences In March 02.26.13 | 04:02 pm
- Endocyte Reports Fourth Quarter And Year End 2012 Financial Results And Business Update 02.25.13 | 04:02 pm
- Endocyte To Present At Upcoming Conferences 02.07.13 | 04:02 pm
- Endocyte Announces Fourth Quarter And Full Year 2012 Earnings Conference Call 02.06.13 | 04:02 pm
- Endocyte To Advance Development Of EC1069, A PSMA-Targeted Small Molecule Drug Conjugate Therapy For Prostate Cancer 01.29.13 | 04:01 pm
Press Releases for ECYT
- Merck And Endocyte Announce Acceptance For Review Of European Marketing Authorization Applications For Vintafolide And Companion Diagnostic Etarfolatide For Folate-Receptor Positive Platinum-Resistant Ovarian Cancer - Business Wire 11.27.12 | 08:11 am
- Merck And Endocyte Enter Exclusive Worldwide Agreement To Develop And Commercialize Phase III Cancer Candidate Vintafolide (EC145) - Business Wire 04.16.12 | 07:04 am
Partner Headlines for ECYT
- Company News for April 17, 2012 - Corporate Summary - Zacks 04.17.12 | 10:04 am
- Morning Market Movers - Benzinga 04.16.12 | 09:04 am
- Top 30 Rallying Small Cap Stocks With Significant Institutional Buying - Seeking Alpha 06.29.11 | 09:06 am
- Company News for April 27, 2011 - Corporate Summary - Zacks 04.27.11 | 10:04 am
- 5 Oncology Drugs Available for Partnering - Seeking Alpha 04.27.11 | 09:04 am
- 7 Diverse U.S. IPOs Test Investor Appetites This Week - Seeking Alpha 02.13.11 | 06:02 am
